Thus, IDO1 is considered a tumor immune checkpoint, and the efficacy of IDO1 inhibitors, alone or in combination with other drugs (e.g., immune checkpoint inhibitors), has been extensively studied in cancer immunotherapy48,49. The gene discussed is IDO1; the disease is cancer.